PSTV – plus therapeutics, inc. (US:NASDAQ)

News

Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Plus Therapeutics Expands CNSide Assay Platform to State of California [Yahoo! Finance]
Plus Therapeutics Expands CNSide Assay Platform to State of California
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com